glp-1 glp-2 glp-3 Recent updates on agonists: Current advancements & challenges If you've been bombarded with

It does not constitute medical advice, diagnosis, or treatment recommendations of any kind

Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial

Most-engaged members lost 25.2% more weight at week 40 and persisted 2.2x longer on medication program than least-engaged members using the Noom app, demonstrating the benefits of combining GLP-1 medication with Nooms GLP-1 Companion behavior-change program PRINCETON, N.J., February 4, 2026 Noom, the leading behavior change company, today shared new real-world findings from tens of thousands of members, showing a clear relationship: members who engage more with Nooms leading GLP-1 Companion app tend to lose more weight and stay on a medication program longer

M., Tripodi, F., Rossi, R., Navarro-Cremades, F